drugset
drugset / Trial / NCT06706622

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622 ↗

Phase 3 Active not recruiting 401 enrolled H. Lundbeck A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).

Timeline

Start
2024-12-03
Primary completion
2028-02-17
Completion
2029-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlenetug Monoclonal antibody — Intravenous

Indications

multiple system atrophy